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Almost half of all individuals affected by intellectual disability (ID) remain undiagnosed. In the Solve-RD project,
exome sequencing (ES) datasets from unresolved individuals with (syndromic) ID (n = 1,472 probands) are
systematically reanalyzed, starting from raw sequencing files, followed by genome-wide variant calling and new
data interpretation. This strategy led to the identification of a disease-causing de novo missense variant in TUBB3
in a girl with severe developmental delay, secondary microcephaly, brain imaging abnormalities, high hyper
metropia, strabismus and short stature. Interestingly, the TUBB3 variant could only be identified through
reanalysis of ES data using a genome-wide variant calling approach, despite being located in protein coding
sequence. More detailed analysis revealed that the position of the variant within exon 5 of TUBB3 was not
targeted by the enrichment kit, although consistent high-quality coverage was obtained at this position, resulting
from nearby targets that provide off-target coverage. In the initial analysis, variant calling was restricted to the
exon targets ± 200 bases, allowing the variant to escape detection by the variant calling algorithm. This phe
nomenon may potentially occur more often, as we determined that 36 established ID genes have robust off-target
coverage in coding sequence. Moreover, within these regions, for 17 genes (likely) pathogenic variants have been
identified before. Therefore, this clinical report highlights that, although compute-intensive, performing genomewide variant calling instead of target-based calling may lead to the detection of diagnostically relevant variants
that would otherwise remain unnoticed.

1. Introduction
Approximately 1% of the population is affected by intellectual disability
(ID) (Maulik et al., 2011), but as the disorder is genetically and clinically

highly heterogeneous, individual genetic causes are very rare, which com
plicates the diagnostic process and the identification of new disease-gene
associations (Vissers et al., 2016). As a result, ~50–70% of individuals
with ID remain undiagnosed (Srivastava et al., 2019). To overcome the
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problem of rarity and aiming to provide individuals with a diagnosis, the
Solve-RD project (Zurek et al., 2021) comprises long-term sharing and sys
tematic reanalysis of next generation sequencing and phenotypic data of 19,
000 unsolved rare disease cases from four European Reference Networks
(ERNs), including ~5,000 cases with (syndromic) ID from ERN-ITHACA
(Intellectual Disability, TeleHealth and Congenital Anomalies; htt
ps://ern-ithaca.eu/). In contrast to recent studies on unsolved cohorts that
reanalyzed variant calling files (Satterstrom et al., 2020) or pooled (de novo)
variants (Kaplanis et al., 2020), in Solve-RD, new mapping and
genome-wide variant calling is the starting point for reanalysis. Reanalysis
strategies using genome-wide calling potentially increase diagnostic yield,
as enrichment kits are often incomplete, despite the efforts aimed at the
enrichment of all protein coding sequences (Ballester et al., 2016). By not
restricting variant calling to (extended) targets of enrichment, the intrinsic
imperfection of enrichment strategies to generate off-target coverage (Bal
lester et al., 2016) can be exploited to rescue some of the missing regions.
TUBB3 encodes the neuron-specific β-tubulin-3. Pathogenic TUBB3
missense variants alter microtubule stability (Poirier et al., 2010; Tischfield
et al., 2010) and impair axonal guidance in brain development (Huang et al.,
2018), causing a spectrum of neuronal migration disorders (Poirier et al.,
2010; Tischfield et al., 2010; Huang et al., 2018; Dentici et al., 2020;
Fukumura et al., 2016; Shimojima et al., 2016; Whitman et al., 2016).
Pathogenic variants can clinically and functionally be distinguished, and
either increase microtubule stability, causing congenital fibrosis of extra
ocular muscles type 3A (MIM#600638) (Tischfield et al., 2010), or impair
microtubule stability, leading to the highly variable phenotype of complex
cortical dysplasia with other brain malformations type 1 (MIM#614039)
(Poirier et al., 2010). A merge of both phenotypes has also been reported
(Whitman et al., 2016).
We describe a disease-causing TUBB3 variant identified in systematic
reanalysis of exome sequencing (ES) data under the collaborative efforts of
the Solve-RD project and ERN-ITHACA. Our clinical report illustrates the
importance of starting reanalysis with raw sequencing data and stresses the
diagnostic potential of genome-wide variant calling, especially in reanalysis.

2.4. Variant identification
Systematic reanalysis of ES data in Solve-RD is described by Matalonga
et al. (2021). The pipeline includes genome-wide variant calling (i.e. not
restricted to the targets of the ES enrichment kit) with GATK (v3.6) (Poplin
et al., 2017) to the GRCh37/Hg19 genome build, i.e. hs37d5, as used by
Phase2 of the 1000 GP. Variants in genes associated with ID were anno
tated and prioritized by applying the following filtering parameters: 1)
coverage depth ≥8 and genotype quality ≥20, 2) gnomAD (Karczewski
et al., 2019) allele frequency <1%, 3) internal RD-Connect allele frequency
<2%, 4) “Likely pathogenic” (ACMG, class 4) or “Pathogenic” (ACMG,
class 5) in ClinVar (Landrum, 2018). Prioritized variants were interpreted
in the context of the phenotype and visualized in the Integrative Genomics
Viewer (IGV) (Robinson, 2011) alongside the exome data of the parents.
2.5. Sanger and amplicon-based deep sequencing
Variant validation by Sanger sequencing was performed using a routine
diagnostic workflow (de Ligt et al., 2012). To exclude low-level mosaicism
in the father, amplicon-based deep-sequencing was performed on the Ion
Torrent platform from Life Technologies (Gilissen et al., 2014). PCR
amplicons were generated in accordance with standard protocols, followed
by read processing and alignment using JSI SeqNext Version 5.1.0 Build
503 (FW: GTGCGGAAGGAGTGTGAAAA; RV GGCATGAAGAAGTGCAGG).
2.6. Detecting off-target coverage on coding sequence and intersection
with HGMD variants
Occurrence of off-target coverage on coding sequence across in
dividuals was analyzed for enrichment kits Agilent V4 and V5 (Sure Select
All Exons; GRCh37/Hg19), as ~70% of ES datasets shared for ERN ITHACA
in the Solve-RD consortium was generated after enrichment with Agilent
V4 or V5. We used 20 representative ES datasets for both kits, and defined
robust off-target coverage occurring consistently across individuals at
depth sufficiently for variant calling if 95% of tested individuals showed
coverage exceeding 20-fold at coding sequence (Gencode v31 (Frankish
et al., 2019)) located outside extended targets of the respective enrichment
kit (genomic coordinates of the exome targets±200bp of Agilent V4 and
V5). For the resulting regions, an intersection was made with
disease-causing (DM) or likely disease-causing (DM?) SNVs/indels reported
in HGMD Professional (Stenson et al., 2003) with specific attention for
genes associated to ID (Radboudumc diagnostic ES ID gene panel DG3.1.0,
comprising 1,392 genes) (Radboudumc. Intellectual, 2021).

2. Materials (subjects) and methods
2.1. Patient inclusion
In compliance with the local ethical guidelines and the Declaration of
Helsinki, all individuals (or legal representatives) in the Solve-RD project
provided informed consent. The Radboudumc institutional review board
approved the study (2018–4986). For publication of photos, additional
consent was obtained.

3. Results

2.2. Initial diagnostic ES analysis

3.1. Clinical characteristics

In 2014, diagnostic ES was performed locally as described previously (de
Ligt et al., 2012). Of essence for this clinical report, exome enrichment was
performed using the Agilent V4 Sure Select All Exons (GRCh37/Hg19)
enrichment kit followed by sequencing on a HiSeq2000 Sequencing System
(Illumina) to an anticipated median 75-fold sequence coverage on target
regions. Variant calling was performed using the GATK HaplotypeCaller
(v3.4) (Poplin et al., 2017), restricted to genomic coordinates of the exome
targets±200bp.

We report on a 16-year-old female proband with severe ID, for whom
extensive diagnostic testing in a university medical center in 2014 could not
identify the (genetic) diagnosis. The proband was the first child from
healthy, non-consanguineous parents and had a healthy brother and sister.
Besides hyperemesis gravidarum, pregnancy was uneventful. Spontaneous
vaginal delivery occurred at 42 weeks of gestation, and although delivery
was complicated by meconium-stained amniotic fluid, there were no prob
lems in the neonatal period (Apgar scores 9/9/10 after 1/5/10 min
respectively; birth weight 3,480 g, − 0.7 SD). At three months of age,
developmental delay was evident, characterized by delayed motor and
communicative milestones with notably quiet and undemanding behavior.
Over the course of the first year, in which she was hospitalized for pneu
monia and hypovolemic shock resulting from rotavirus gastro-enteritis, she
gradually developed secondary microcephaly (head circumference at birth
0 SD, at 1 year − 2 SD). Brain MRI (age 2 years and 2 months; Fig. 1) showed
hypoplasia of the corpus callosum, a reduced volume of supratentorial white
matter with delayed myelination, dysplasia of basal ganglia, thalami and
cerebellum, and an enlarged ventricular system, mainly of the lateral

2.3. Solve-RD data-sharing for systematic reanalysis
Human Phenotype Ontology (HPO)-standardized phenotypic data and
BAM files of ES were uploaded to the RD-Connect Genome-Phenome
Analysis Platform (GPAP; https://platform.rd-connect.eu/), and deposited
at European Genome-Phenome Archive (EGA; accession numbers
EGAZ00001527579, EGAZ00001534566 and EGAZ00001549096 for
index, father and mother respectively), as part of the Solve-RD infrastructure
(Zurek et al., 2021; Matalonga et al., 2021).
2
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Fig. 1. Brain MRI displays structural brain
abnormalities. Sagittal (A) and axial (C–E)
T1-weighted and axial T2-weighted (B) MR
images of the brain at age 2 years and 2
months show several structural brain ab
normalities. There is general enlargement of
the ventricular system, mostly affecting the
lateral ventricles (indicated by green aster
isks; panel A, B, D), but also the third
ventricle (indicated by a yellow III; panel A)
and the fourth ventricle (indicated by a blue
IV; panel A), communicating with a mega
cisterna magna (indicated by a magenta star;
panel A). The corpus callosum is hypoplastic
(red arrowhead; panel A, D) and the cere
bellum and cerebellar vermis show
dysplasia, with abnormal morphology and
orientation of folia (dotted white line; panel
C). The basal ganglia and thalami are
dysplastic, with an abnormal round appear
ance, and individual structures cannot be
distinguished clearly (dashed orange line;
panel D, E). Additionally, there is a reduced
volume of supratentorial white matter
(globally seen in panel B, D, E). . (For
interpretation of the references to colour in
this figure legend, the reader is referred to
the Web version of this article.)

ventricles (left more prominently enlarged than right), but also of the third
and fourth ventricle, with the fourth ventricle communicating with an
enlarged cisterna magna. There were no signs of cortical malformation.
Electromyography and nerve conduction studies (age 2 years) did not show
signs of an associated peripheral neuropathy or myopathy. There was no
epilepsy. At ages 11 and 15 years, she was tested by SON-R 2.5–7, a nonverbal intelligence test, which showed a severe developmental delay and
intellectual disability (chronological age 11 years and 11 months: develop
mental age of 2 years and 10 months; chronological age 15 years and 9
months: developmental age 2 years and 11 months, developmental age in
fluid reasoning 3 years, developmental age at performance scale 2 years and

9 months). At 15 years of age, she had a vocabulary of 10 words, with a more
developed receptive vocabulary than expressive vocabulary (WPPSI-III-NL
4–7;11 subscale General Language Composite (GLC) at chronological age 15
years and 9 months: developmental age 5 years and below 2 years and 7
months respectively). Other medical problems included high hypermetropia
(+7D/+7.5D), convergent strabismus, short stature (− 2.5SD), scoliosis,
susceptibility to urinary and upper respiratory tract infections, constipation,
factor V Leiden thrombophilia and behavioral problems (automutilation,
sleep disturbances, phonophobia). She had minor facial dysmorphisms,
consisting of a round face, with deep-set eyes and large palpebral fissures, a
low nasal bridge and a prominent chin (Fig. 2), a mild pectus carinatum and

Fig. 2. Facial photographs of the proband. Frontal (panel A, C) and profile (panel B, D) facial photographs of the proband at age 17 years and 4 months (panel A, B)
and at age 8 years and 2 months (panel C, D), showing mild facial dysmorphisms in the proband: she has a round face with deep-set eyes and large palpebral fissures,
a low nasal bridge and a prominent chin.
3
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Fig. 3. IGV visualization of alignment files of index, father and mother. IGV visualization of alignment files of index (top), father (middle) and mother (bottom),
showing the chr16:g.90001622G>A variant in the heterozygous state in the index (ref 38; alt 40), in one sequencing read of the father (ref 62; alt 1) and in no reads
of the mother (ref 60; alt 0).

nipple retraction. Diagnostic evaluation consisted of karyotyping (at the age
1 of year), metabolic screening (age 1 year and 2 years), biochemical analysis
of cerebrospinal fluid and blood (age 2 years), subtelomeric MLPA (age 2
years), 250K SNP array (age 4 years), targeted GRIN2B Sanger analysis (age
10 years), and trio-based ES (age 10 years), but did not result in an expla
nation for the phenotype.

proband. The TUBB3 missense variant was absent from gnomAD
(v2.1.1) (Karczewski et al., 2019), had a CADD-PHRED score of 24.8
(Rentzsch et al., 2019) and TUBB3 is highly intolerant to variation
(Z-score missense 4.85; pLI 0.97) (Karczewski et al., 2019), all sup
porting variant pathogenicity. In addition, the variant was previously
reported as “Likely pathogenic” in ClinVar (VCV000372654.1)(Land
rum, 2018), but without any clinical description. Reanalysis did not
identify other clinically relevant (de novo) variants.
Manual inspection of sequence alignment files in IGV clearly showed
the presence of the variant in the proband (Fig. 3), which was subse
quently confirmed by Sanger sequencing. Sanger analysis of both
parental samples indicated the variant to be of de novo origin. However,
the BAM file of the father showed the same variant in 1 of 63 reads (Fig. 3),

3.2. Systematic reanalysis revealed a likely pathogenic TUBB3 variant
Data of the proband and parents were included in the Solve-RD
project. Variant calling and annotation with the Solve-RD pipeline
revealed a heterozygous de novo variant in TUBB3:Chr16(GRCh37/
Hg19):g.90001622G>A;NM_006086.3:c.763G>A;p.(Val255Ile) in the
4
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Fig. 4. Exon 5 of TUBB3 and (extended) target regions used in variant calling. A schematic representation of the last part of TUBB3, including the variant identified
in the proband. Shown in black are target regions of Agilent V4 and V5 enrichment kits, in orange target regions extended by 100bp on each side (the regions where
sequence can be expected) and in green target regions extended by 200bp on each side (the regions used for variant calling in initial diagnostic analysis). The blue bar
at the bottom visualizes genome-wide variant calling as done in the Solve-RD project. . (For interpretation of the references to colour in this figure legend, the reader
is referred to the Web version of this article.)

potentially indicative of low-level mosaicism (Wright et al., 2019). Due to
the technical limitations of Sanger sequencing to detect such low-level
mosaicism (Acuna-Hidalgo et al., 2015), we therefore continued with
amplicon-based deep sequencing of the TUBB3 variant on DNA derived
from blood of the father to a sequence depth of 11,000-fold. This
confirmed the absence of the variant in father (G: 99.89%; A: 0.05%; T:
<0.01%; C: 0%, with percentages of A, T and C equal to background noise
resulting from PCR artefacts), and its de novo origin in the proband.

3.4. Off-target covered regions disregarded in targeted variant calling
coincide with known ID genes and previously reported pathogenic variants
To assess the overall impact of our conclusions, we checked the
targets for TUBB3 in Agilent V5, showing improved capture of TUBB3,
with five additional targets compared to V4, of which three target exon 5
including the region of the variant (Fig. 4).
Next, we analyzed whether other regions of the coding sequence show
off-target coverage but are disregarded in variant calling for both Agilent V4
and V5 enrichment kits (Table 1). First, we determined which protein coding
sequences showed robust off-target coverage (≥20-fold), consistently pre
sent across multiple individuals (95% of 20 individuals), and then created
the overlap with regions not included in targeted variant calling based on the
extended targets ( ±200bp). This analysis detected a total of 840,347 and
761,594 nucleotides (1.95% and 1.76% of Gencode v31) in 1,537 and 1,298
of such regions, affecting 1,031 and 659 genes for Agilent V4 and V5,
respectively. This included 36 established ID genes, including TUBB3 for V4,
and 21 ID genes for V5. By intersecting the results of V4 with HGMD Pro
fessional (Stenson et al., 2003), we found that 262 unique (likely) pathogenic
SNVs/indels (DM? 33; DM: 229) affect 17 of these 36 ID genes. To a lesser
extent, this was also observed for V5, where we showed 71 (likely) patho
genic variants (DM? 6; DM: 65) to be located in these regions, affecting 8 of
21 ID genes (Table 1, Supplementary Table 1).

3.3. The variant calling algorithm in initial ES analysis did not detect the
TUBB3 variant
Next, we retrospectively analyzed why the TUBB3 variant was not
identified before, as TUBB3 was included in the targets of the enrich
ment kit used for ES in this trio, and the gene was already described in
literature in relation to intellectual disability and cortical dysplasia for 4
years at the time of initial diagnostic ES (Poirier et al., 2010). Addi
tionally, in the diagnostic workflow used for individuals with intellec
tual disability, the interpretation of detected de novo variants in
trio-based ES was performed invariably and with priority. Therefore,
we first re-examined the output of the variant calling pipeline (anno
tated VCF) used in initial analysis and found that the variant was not
called by the variant calling algorithm. Assessment of the regions
considered in variant calling, showed that the variant is located in a
region of the alignment not included in the extended targets for variant
calling (target ± 200bp), and therefore ignored by the variant calling
algorithm (Fig. 4). Hence, we concluded that the combination of
target-based calling and the exome enrichment kit used explains why the
initial diagnostic ES did not lead to the detection of the TUBB3 variant.

4. Discussion
Through systematic reanalysis in the Solve-RD project, we found a likely
pathogenic missense variant in TUBB3 (c.763G>A;p.(Val255Ile)) in a 16year-old female proband with severe ID. The variant is causative to the
proband’s phenotype, which consists of severe developmental delay, stra
bismus, microcephaly and structural brain abnormalities and fits the

Table 1
Genes and reported (likely) pathogenic variants in off-target covered regions disregarded in targeted variant calling.
Kit

Regions with ≥20x
coverage in 95% of
individuals

Agilent
1,537
V4
Agilent
1,298
V5
Overlap V4 and V5

All genes

Genes associated with ID

# unique
genes

# genes with previously
reported (likely)
pathogenic variants in
these regions

# of reported unique
(likely) pathogenic
variants in these
regions

# ID genes (%
of all known
ID genes)

# ID genes with previously
reported (likely)
pathogenic variants in
these regions

# of reported unique
(likely) pathogenic
variants in these
regions

1,031

133

884

36 (2.6%)

17

262

659

58

426

21 (1.5%)

8

71

420

34

94

16 (1.1%)

5

13

5
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phenotypic spectrum of complex cortical dysplasia with other brain
malformations-1 (CDCBM1; MIM#614039) (Poirier et al., 2010; Dentici
et al., 2020; Fukumura et al., 2016; Shimojima et al., 2016). Although the
proband does not exhibit the typical cortical dysplasia phenotype, the
peculiar combination of several of the other structural abnormalities seen in
brain imaging of the proband, specifically dysplasia of the cerebellum,
thalami and basal ganglia, hypoplasia of the corpus callosum, and enlarge
ment of the ventricular system, is common in patients affected by pathogenic
TUBB3 missense variants (Dentici et al., 2020).
This variant, which explains the phenotype in this individual, could only
be identified by subjecting sequencing data to genome-wide variant calling.
Diagnostic variant calling pipelines were limited to detect this variant in
exon 5 of TUBB3, as exon 5 was not completely targeted by the Agilent V4
enrichment kit, and the prior pipeline was dependent on targeted-based
variant calling±200bp. Of note, the decision to use±200bp extended
target calling was already double the recommendation of±100bp done by
Agilent.
Despite not being fully targeted by the capture kit, exon 5 of TUBB3
in this proband-parents trio showed sufficient off-target coverage, with
the variant clearly detectable in the proband, enabling the genome-wide
variant caller in the Solve-RD pipeline to identify the variant. To
determine whether our observation was an isolated case, or whether this
phenomenon may occur for multiple ID genes, we assessed the impact at
exome-wide level. Exome-wide analysis for two enrichment kits across
20 individuals showed that interpretable off-target coverage in proteincoding sequence is generated for >1,000 genes in V4, and ~650 genes in
V5. The use of target-based variant calling algorithms ( ±200bp) would
disregard at least part of the coding sequence of these genes. The clinical
relevance of these genes is highlighted by the fact that for multiple ID
genes disease-causing variants similar to this variant in TUBB3 have
been reported in regions escaping variant calling. The impact may even
be underestimated as we have used targets±200bp in diagnostic variant
calling, already calling more off-target bases than recommended.
As reanalysis of existing ES data is a process used more often for
individuals who remained undiagnosed at first diagnostic ES trajectory,
the use of genome-wide variant calling should be considered. In
particular if data were generated using ‘older’ exome enrichment kits, as
it is to be expected that more recent enrichment kits keep improving and
aim to resolve the issue reported here. Whether genome-wide variant
calling should be used as a generalized approach for exome data during
the first diagnostic analysis, is more difficult to assess as this depends on
multiple factors, including the capture kit used and the (computational)
infrastructure available.
In summary, we describe a female proband diagnosed with a de novo
missense variant in TUBB3, through systematic, large-scale reanalysis on
a cohort of unexplained (syndromic) ID cases within Solve-RD. We show
that performing new variant calling enables detection of variants missed
by variant calling in initial analysis, stressing the relevance of sharing
raw data, as alternative approaches of data-sharing and reanalysis
would have failed to identify these (potentially causative) variants. As
the same issue also occurs for other (ID) genes, especially in older
enrichment kits, this implies that genome-wide variant calling, although
computationally demanding, expands the potential of ES and may
effectuate new diagnoses in other unexplained cases of ERN ITHACA.
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